These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30833139)

  • 1. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Li R; Spiess PE; Gilbert SM; Necchi A
    Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative systemic therapy for bladder cancer.
    Eulitt PJ; Bjurlin MA; Milowsky MI
    Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
    Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
    Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
    Janisch F; Rink M; Shariat SF
    BJU Int; 2020 Jun; 125(6):753-755. PubMed ID: 32011069
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
    Balar AV
    Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.
    Yang Y; Jain RK; Glenn ST; Xu B; Singh PK; Wei L; Hu Q; Long M; Hutson N; Wang J; Battaglia S; George S
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
    Noro D; Hatakeyama S; Yoneyama T; Hashimoto Y; Koie T; Kawaguchi T; Ohyama C
    Med Oncol; 2017 Jun; 34(6):117. PubMed ID: 28500617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
    Darling HS; Bellmunt J
    Expert Opin Biol Ther; 2019 Jul; 19(7):685-695. PubMed ID: 31046476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
    Bandini M; Ross JS; Raggi D; Gallina A; Colecchia M; Lucianò R; Giannatempo P; Farè E; Pederzoli F; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Deho' F; Ali SM; Madison R; Chung JH; Salonia A; Briganti A; Montorsi F; Necchi A
    J Natl Cancer Inst; 2021 Jan; 113(1):48-53. PubMed ID: 32516377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Pederzoli F; Bandini M; Raggi D; Marandino L; Basile G; Alfano M; Colombo R; Salonia A; Briganti A; Gallina A; Montorsi F; Necchi A
    Eur Urol; 2021 Sep; 80(3):319-322. PubMed ID: 34053782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
    Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.